Drug Discovery

Aitia is advancing drug discovery programs in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease. These programs begin with novel drug targets discovered from our Gemini Digital Twins in each disease and are then genetically validated across multiple Digital Twin cohorts in that disease. Further validation in state-of-the-art pre-clinical systems is performed to add additional evidence to each novel target and then drug candidate programs are initiated across multiple drug modalities.

Aitia is interested in partnering these discovery programs from the earliest phases of discovery through IND to advance these discoveries to the clinic and to patients.